Scrip
NICE to reappraise Celgene's Vidaza for leukaemia following appeal
29 July 2010
Francesca Bruce
NICE, the health technology appraisal institute in England and Wales, will reappraise Celgene's Vidaza (azacitidine) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia following several appeals against the institute's final appraisal determination.
In...
Please Login to read the full article.
29 July 2010
Francesca Bruce
In...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
- Face-to-Face: Trophos - The French firm that hooked Actelion
- Connexios: Harnessing the Indian cost advantage in network biology
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
